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Abstract 
Background: We aimed to determine the effect of sampling time during the day on serum periostin levels in adult 
participants with and without asthma.
Methods: Serum periostin was measured at 2‑h intervals from 0800 to 1800 h in 16 adult participants with stable 
asthma prescribed inhaled corticosteroid and long‑acting beta‑agonist therapy, and in 16 otherwise healthy partici‑
pants without asthma. Mixed linear models were used to compare time zero (08:00 h) with subsequent measurement 
time for serum periostin for both groups.
Results: In both asthma and non‑asthma, the mean (SD) serum periostin levels continuously reduced during the day 
from 53.5 (13.6) ng/mL at 0800 h to 50.9 (13.4) ng/mL at 1800 h (difference log periostin −0.05, P ≤ 0.001) and 50.5 
(13.0) ng/mL at 0800 h to 46.2 (11.5) ng/mL at 1800 h (difference log periostin −0.08, P ≤ 0.001) respectively.
Conclusions: Periostin values are higher in the morning compared with the afternoon in asthmatic and non‑asth‑
matic adults. The small magnitude of the variation in serum periostin levels suggests that the time of day in which the 
serum periostin measurements are made is unlikely to influence treatment decisions if a specific serum periostin level 
is used to predict treatment responsiveness.
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Background
Asthma is a disease with an increasing global burden [1, 
2]. Appropriate biomarkers may assist with determining 
clinical phentoypes, predicting treatment responsive-
ness, and directing personalized therapy [3, 4]. Currently 
recognized biomarkers include fraction of expired nitric 
oxide (FeNO), induced sputum and blood eosinophil 
levels, and total and specific IgE [3, 4]. Recently serum 
periostin, a matricellular protein generated by airway 
epithelial cells and partly regulated by IL-13, has been 
proposed as a biomarker with a potential clinical role in 
severe asthma [5–8]. Serum periostin is a marker of type 
2 inflammation, and has a stronger association with air-
ways eosinophilia in severe asthma than blood eosinophil 
levels and FeNO [6]. High serum periostin levels may also 
predict responsiveness to monoclonal antibody therapy 
directed against IL-13 [9] IgE [10] and IL-4Ra [11]. This 
has led to the consideration of periostin as a predictive 
biomarker to identify patients most likely to respond to 
such monoclonal antibody therapies.
Recently we determined the reference ranges for serum 
periostin in two populations, an adult population with-
out asthma or COPD [12], and an adult population with 
symptoms of airflow obstruction, predominantly adults 
with diagnosed asthma [13]. Clinical interpretation 
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would be enhanced further by determining any time-
related variation in periostin measurements, particularly 
within the typical timeframe covered by clinic-based 
assessments in primary or specialist health practice. 
Time-related variations are reported for other type-2-re-
lated biomarkers in asthma such as sputum and blood 
eosinophils [14–18], and FeNO [19–21]. Measurements 
of these biomarkers are generally higher overnight and in 
the morning than in the afternoon.
We estimated the time-related variation in serum peri-
ostin levels in adults with asthma receiving maintenance 
ICS and long-acting beta agonist (LABA) therapy; the 
clinical population in which serum periostin levels are a 
predictor of responsiveness to monoclonal antibody ther-
apy directed against IL-4, IL-13 and IgE [9–11]. We also 
estimated the time-related variation in serum periostin 
levels in adults without asthma, and compared the time-
related variations in serum periostin with those of other 
markers of type-2 dominant asthma, FeNO and blood 
eosinophils.
Methods
In this non-experimental cohort observational study 
we recruited adults aged 18–75  years of age, compris-
ing 16 participants with asthma who were prescribed 
maintenance ICS and LABA therapy, (asthma group), 
and 16 participants who neither had a doctor diagnosis 
of asthma, symptoms of wheeze, or inhaler use in the 
past 12  months (non-asthma group). Exclusion criteria 
for both the asthma and non-asthma groups included: 
chronic bronchitis or COPD, known pregnancy, active 
(current, or within the three weeks prior to the visit) 
upper or lower respiratory tract infection, any of the 
following within the last 3  months; hospital admission, 
major surgery requiring general anesthetic, dental extrac-
tions or root canal procedures and bone fracture and any 
significant comorbidities or any safety concerns at the 
investigator’s discretion.
Study procedures
Participants attended the clinical trials unit (CTU) at 
Capital and Coast District Health Board (CCDHB Wel-
lington Hospital) for an initial visit (Visit 1) where the 
following procedures were completed: written informed 
consent, completion of a general health questionnaire 
[22], measurement of body mass index (BMI) and train-
ing in spirometry technique. Participants then attended 
the CTU on a second occasion (Visit 2) where blood 
samples were drawn every 2 h for serum periostin levels 
and peripheral blood eosinophil counts. Following each 
blood sample measures of FeNO, forced expiratory vol-
ume in 1  s (FEV1) and forced vital capacity (FVC) were 
performed in accordance with ATS criteria [23, 24]. Six 
measurements were taken over the 10-h period. Partici-
pants with asthma also completed the asthma control 
questionnaire-5 (ACQ-5) and the asthma quality of life 
questionnaire with standardized activities (AQLQ(S)) 
[25, 26].
Medication use
Participants with asthma were advised to take their reg-
ular ICS and LABA treatment in the morning prior to 
attending the clinic on Visit 2, and not to take any medi-
cation during the 10-h study period.
Study power
The clinically important difference in serum periostin is 
unknown. We chose a sample size of 16, with 80% power, 
alpha 5%, based on a paired t test, to detect a paired 
difference of 0.75 standard deviations, for continuous 
variables, which constitutes in general terms a ‘large’ dif-
ference. This same sample size also has good precision 
for estimation of variance.
Statistical methods
Simple data descriptions are shown for the variables by 
asthma status. Serum periostin and FeNO were analyzed 
on the natural logarithm transformed scale. The expo-
nent of a difference in logarithms can be interpreted as a 
ratio of geometric means. No transformations were done 
for other variables.
Mixed linear models were used to compare time zero 
with subsequent measurement time by asthma groups. 
The correlation structure for the repeated measures 
allowed for different correlations between the different 
measurements on the same participants, the ‘unstruc-
tured’ option in the statistical software. Simple unpaired t 
tests were used to compare the baseline values for asthma 
versus non-asthma.
A post hoc analysis was undertaken to determine the 
proportion of adults with asthma that would change clas-
sification from ‘high periostin’ to ‘low periostin’, or from 
‘low periostin’ to ‘high periostin’ based on the 0800 and 
1800  h periostin levels, utilizing the proposed periostin 
cut point of 50 ng/mL, used to determine responsiveness 
to monoclonal antibody therapies [9, 10].
SAS version 9.3 was used.
Results
Participant characteristics
The flow of participants in the study is shown in Fig. 1. 
Baseline characteristics for asthma and non-asthma par-
ticipants are shown in Table  1. All asthma participants 
were prescribed maintenance ICS/LABA inhaler therapy 
with a mean daily dose of 489 µg/day of fluticasone pro-
pionate (FP) or equivalent as the ICS component. The 
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non-asthma participants were younger and had a lower 
BMI than the asthma participants. There were two cur-
rent smokers, both of whom had asthma.
There was no statistically significant difference in peri-
ostin levels between the asthma and non-asthma groups 
at baseline (0800); difference (95% CI) in logarithm peri-
ostin 0.058 (−0.13 to 0.25), P = 0.54. This is equivalent to 
a mean ratio of serum periostin levels in the asthma ver-
sus non-asthma group of 1.06 (0.88–1.28). There was no 
statistically significant difference in FeNO levels between 
the asthma and non-asthma groups at baseline (0800); 
difference (95% CI) in logarithm FeNO 0.16 (−0.25 
to 0.56), P =  0.43. This is equivalent to a mean ratio of 
FeNO levels in the asthma versus non-asthma group of 
1.17 (0.78–1.76). There was weak evidence of a higher 
mean blood eosinophil count, 0.31 × 109/L in the asthma 
group, compared to 0.19 × 109/L in non-asthma, differ-
ence (95% CI), 0.11 (−0.005 to 0.23), P = 0.06.
Day‑time changes in asthma
The serum periostin level decreased from a mean of 
53.5  ng/mL, at 0800  h, to 50.9  ng/mL at 1800  h. There 
Fig. 1 Flow of participants through study
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Table 1 Baseline characteristics of participants
Variable N = 16 Mean (SD) Median (IQR) Min to max
Asthma
Age (years) 45.4 (19.7) 47 (25 to 63.5) 19–73
BMI (kg/m2) 32.2 (5.3) 33.4 (28.8–35.5) 20.9–42.2
FEV1 % predicted
a 90.5 (18.1) 96.6 (81.9–102.9) 50.6–111.6
FEV1/FVC ratiob 0.82 (0.04) 0.81 (0.79–0.85) 0.77–0.89
Mean ICS dosec 489 (105.3) 500 (500–500) 200–500
Eosinophil count (×109/L)d 0.31 (0.20) 0.25 (0.20–0.35) 0–0.7
FeNO (ppb) 26.1 (13.3) 23.5 (16–36) 7–55
Periostin (ng/mL) 53.5 (13.6) 51.7 (41.5–63.7) 33.9–76.2
ACQ‑5e 1.3 (1.2) 1.2 (0.4–1.4) 0–4.0
AQLQ(S) 5.71 (1.22) 6.05 (5.5–6.35) 2.8–7.0
Categorical variables Number (%)
ACQ ≤ 0.75 5 (31)
ACQ ≥ 1.50 3 (19)
ACQ > 0.75 to <1.50 8 (50)





Variable N = 16 Mean (SD) Median (IQR) Min to max
Non‑asthma
Age (years) 28.1 (12.7) 23 (21–30.5) 20–68
BMI (kg/m2) 23.8 (2.8) 22.8 (22.1–27.0) 19.7–28.3
FEV1 % predicted
a 97.9 (10.5) 96.3 (90.8–105.7) 80.5–120.9
FEV1/FVC ratio
b 0.85 (0.03) 0.86 (0.85–0.88) 0.77–0.88
Eosinophil count (×109/L) 0.19 (0.11) 0.20 (0.10–0.25) 0.10–0.50
FeNO (ppm) 22.3 (14.1) 19.5 (15.5–24.5) 6.0–68.0
Periostin (ng/mL) 50.5 (13.0) 49.4 (42.5–62.7) 28.6–70.5
Categorical variables Number (%)




SD standard deviation, IQR interquartile ratio, BMI body mass index, ICS inhaled corticosteroid, FeNO fraction of exhaled nitric oxide
a FEV1 post‑bronchodilator, expressed as % of normal predicted values
b FEV1/FVC ratio, pre‑bronchodilator
c ICS daily dose expressed as fluticasone propionate equivalent (microg/day)
d Eosinophil laboratory reference range: 0.0–0.5 × 109/L, (measured in increments of 0.1)
e ACQ‑5: asthma control questionnaire‑5, a score >1.5 indicates uncontrolled asthma [26]
f Atopy: a history of eczema and/or seasonal rhinitis
was strong evidence, overall P  <  0.001, that the means 
by time were different, (Table 2; Fig. 2a; Additional file 1: 
Table S1, Figure S1). Compared with baseline, the log 
periostin was significantly lower from the 4-h (1200  h) 
to the 10-h (1800 h) time points, and the size of the dif-
ference remained constant from the 4-h time point. The 
ratio of geometric mean serum periostin compared to 
baseline was between 0.95 and 0.98.
In a post hoc analysis of the asthma group, there was 
a change in classification from ‘high periostin’ to ‘low 
periostin’, based on the 0800 and 1800  h periostin lev-
els, utilizing the proposed cut point of 50 ng/mL in 1/16 
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participants (50.3 and 48.2  ng/mL at 0800 and 1800  h, 
respectively) (Additional file  1: Table S1). There was no 
change in classification from ‘low periostin’ to ‘high peri-
ostin’, using the same criteria.
The FeNO decreased during the day from a peak mean 
of 26.1 ppb at 0800 h to lowest level of 21.7 ppb at 1800 h. 
There was strong evidence, overall P  <  0.001, that the 
means by time were different, (Table 3; Fig. 3a, Additional 
file 1: Table S2, Figure S2). Compared with baseline, the 
log FeNO was significantly lower from the 6-h (1400 h) to 
the 10-h (1800 h) time points. The size of the difference 
from the 6-h time point ranged from an estimate differ-
ence (95% CI) of −0.16 (−0.26 to −0.05) to −0.22 (−0.33 
to −0.12). The ratio of geometric mean FeNO compared 
to baseline was between 0.80 and 0.96.
There was some evidence, P  =  0.02, that the mean 
blood eosinophil count differed by time during the 10-h 
period of the study (Table 4) but none of the individual 
comparisons with baseline were statistically significant.
FEV1 % predicted progressively decreased during the 
day from 90.5% at 0800 h to 85.8% at 1800 h (Additional 
file 1: Table S3). No participant received SABA for symp-
tom relief during the 10-h period of the study.
Day‑time changes in non‑asthma
Serum periostin level progressively decreased during 
the day from a mean of 50.5 ng/mL at 0800 h to 46.2 ng/
mL at 1800 h. There was strong evidence, P < 0.001, that 
the means by time were different, (Table 2; Fig. 2b; Addi-
tional file  1: Table S4, Figure S3). The magnitude of the 
difference compared with baseline was, as for the asthma 
group, stable from the 4-h (1200 h) to the 10-h (1800 h) 
time points. The ratio of geometric mean serum periostin 
compared to baseline was between 0.92 and 1.00.
FeNO progressively decreased during the day from 
22.3  ppb at 0800  h to 18.5  ppb at 1800  h. There was 
strong evidence, (P = 0.004), that the means by time were 
different, (Table 3; Fig. 3b; Additional file 1: Table S5, Fig-
ure S4). Compared with baseline, the log FeNO was sig-
nificantly lower from the 10-h (1800 h) time point with 
an estimated difference (95% CI) of 0.17 (−0.28 to −0.05; 
P = 0.005). The ratio of geometric mean FeNO compared 
to baseline was between 0.84 and 0.98.
Blood eosinophil count progressively decreased dur-
ing the day from a mean of 0.19 × 109/L at 0800 h to a 
nadir of 0.13  ×  109/L. There was strong evidence that 
the means were different by time, (P < 0.001) (Table  4). 
Compared with baseline, the blood eosinophil count was 
significantly lower at the 2-, 4-, 6- and 8-h time points 
with estimated differences (95% CI) ranging from −0.06 
(−0.09 to −0.02) to −0.04 (−0.08 to −0.01).
Discussion
This study shows that serum periostin levels vary 
throughout the day in adults with and without asthma, 
with higher levels in the morning in both groups. The 
magnitude of the variation was small, suggesting that 
the time that periostin levels are measured is unlikely to 
influence treatment decisions if predicting responsive-
ness to, or eligibility for monoclonal antibody therapy 
Table 2 Serum periostin (ng/mL) levels at time points during study
SD standard deviation, IQR interquartile range, CI confidence interval
a Difference from baseline is estimated from the mixed‑effects linear model
Time points Periostin
Mean (SD) Median (IQR) Min to max Difference from base‑
line mean (SD)





0 (0800) 53.5 (13.6) 51.7 (41.5–63.7) 33.9–76.2
2 (1000) 52.1 (12.5) 51.3 (40.8–63.0) 32–71.4 −1.4 (2.2) −0.02 (−0.05 to 0.003) 0.08
4 (1200) 51.3 (13.7) 49.3 (39.3–64.8) 29.9–70.8 −2.2 (3.3) −0.05 (−0.07 to −0.02) <0.001
6 (1400) 51.0 (12.7) 51.7 (39.4–61.7) 31.2–69.6 −2.5 (2.5) −0.05 (−0.07 to −0.02) <0.001
8 (1600) 50.6 (12.4) 52.3 (38.9–60.4) 32.3–70.0 −2.9 (3.7) −0.05 (−0.08 to −0.03) <0.001
10 (1800) 50.9 (13.4) 50.3 (38.9–61.2) 30.3–71.6 −2.6 (2.6) −0.05 (−0.08 to −0.03) <0.001
Non‑asthma
0 (0800) 50.5 (13.0) 49.4 (42.5–62.7) 28.6–70.5
2 (1000) 50.3 (13.4) 48.6 (39.7–61.2) 28.7–72.7 −0.2 (2.7) −0.006 (−0.04 to 0.02) 0.71
4 (1200) 47.7 (12.2) 46.3 (39.5–59.7) 27.7–67.0 −2.8 (2.5) −0.06 (−0.09 to −0.03) <0.001
6 (1400) 46.6 (11.3) 45.0 (39.8–53.8) 28.6–65.5 −3.9 (3.6) −0.08 (−0.11 to −0.05) <0.001
8 (1600) 46.5 (11.9) 43.8 (38.6–55.9) 27.9–68.2 −4.0 (2.9) −0.08 (−0.11 to −0.05) <0.001
10 (1800) 46.2 (11.5) 46.6 (37.7–55.0) 29.2–66.3 −4.2 (3.2) −0.08 (−0.11 to −0.06) <0.001
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directed against IL-4Ra, IL-13, IgE or other components 
of type-2 inflammation in asthma.
The median baseline values of 51.7 and 49.4 ng/mL in 
the asthma and non-asthma groups respectively are sim-
ilar to the median levels of 50.1  ng/mL in a population 
without asthma or COPD [12], 53.7 ng/mL in a random 
adult population with a diagnosis of asthma [13], and 
50.2  ng/mL in adults with moderate to severe asthma 
inadequately controlled despite ICS therapy [9]. Inter-
pretation of periostin levels might be confounded by the 
observation that initiation of ICS therapy may result in a 
modest reduction in serum periostin by a mean of 5.3 ng/
mL [13]. Together, these findings suggest that serum per-
iostin is not a measure which can differentiate patients 
with asthma across a range of severity from a population 
without asthma.
The daytime variation we have found with serum peri-
ostin levels is similar to that reported previously for the 
type 2-related biomarkers of sputum and blood eosino-
phils [14–18] and FeNO [19–21]. In allergic subjects 
Fig. 2 Individual joined line plots for Periostin. Panel a shows the asthma group, Panel b shows the non‑asthma group. The bold red line indicates 
the median periostin value
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with mild asthma, sputum eosinophils are about two-
fold higher at 0700  h than at 1600  h [14]. Additionally, 
the early morning increase in sputum eosinophils corre-
lated with enhanced airway obstruction and reversibility, 
suggesting that airway recruitment of eosinophils might 
contribute to circadian variations in lung function in 
patients with asthma [14].
In adults with mild asthma, blood eosinophil counts 
are about 25% higher at 0400  h than at 1600  h [15]. It 
has been observed that the circadian change in blood 
eosinophils and lung function appear to fall into a con-
tinuous range, suggesting that day/night variations in 
airways inflammation and lung function occur as a con-
tinuum, rather than as an all or nothing phenomenon 
[15]. In allergic subjects with moderately severe asthma, 
a circadian variation in blood eosinophil counts was also 
observed with peak values overnight [16]. In healthy sub-
jects, blood eosinophil counts may also vary diurnally, 
being lowest in the morning and highest at night, corre-
lating inversely to blood cortisol levels [17]. The demon-
stration of daytime variation in the non-asthma, but not 
the asthma group in our study is likely to reflect the lack 
of power, low sensitivity of the automated measurement 
of blood eosinophil levels to increments of 0.1 per 109/L, 
and possibly the effect of the maintenance treatment with 
ICS in all asthma participants.
In asthma, there is a variable degree of diurnal varia-
tion in FeNO, which is greatest in uncontrolled disease 
and serves as a predictor of risk of future exacerbations 
[19–21]. The mean diurnal FeNO variation, measured 
as the difference in morning (0700–1000  h) from even-
ing (1800–2100  h) levels over a two-week period, was 
15.6  ppb in uncontrolled asthma subjects compared 
with 8.2  ppb in stable controlled asthma, and 6.1  ppb 
in healthy subjects [21]. In another study of adults with 
asthma, morning FeNO levels were reported to be 14% 
higher than evening levels [19]. In our study we observed 
a mean difference in FeNO between 0800 and 1800 h on 
a single day of 4.4 ppb in controlled asthma and 3.8 ppb 
in non-asthma. Finally, the lesser variability, based on the 
ratio of geometric mean values compared to baseline, of 
serum periostin levels compared with FeNO levels in our 
study is consistent with previous observations that there 
is a lesser intra-patient variability in periostin levels com-
pared with FeNO [9].
The clinical relevance of our findings is illustrated by 
the post hoc analysis in which we determined that only 
one in 16 asthma participants changed their periostin 
classification between ‘high periostin’ and ‘low periostin’, 
based on the 0800 and 1800  h levels, utilizing the pro-
posed periostin cut point of 50 ng/mL, used to determine 
responsiveness to monoclonal antibody therapy directed 
against IL-13 [9], and IgE [10]. Thus daytime variation 
of periostin is unlikely to be an important considera-
tion using the 50  ng/mL cut point. However, the valid-
ity of the cut-point as a predictor of responsiveness will 
need to be confirmed in future studies utilizing the same 
assay and a cut-off needs to be established if other assays 
are used. Although the used assay has a very good pre-
cision around the cut-point of 50  ng/mL (repeatability 
Table 3 FeNO (ppb) levels at time points during study
SD standard deviation, IQR interquartile range, CI confidence interval, FeNO fraction of exhaled nitric oxide
a Difference from baseline is estimated from the mixed‑effects linear model
Time points FeNO
Mean (SD) Median (IQR) Min to max Difference from  
baseline mean (SD)





0 (0800) 26.1 (13.3) 23.5 (16–36) 7.0–55.0 – –
2 (1000) 25.1 (13.3) 24.0 (15–34) 7.0–54.0 −1.0 (5.2) −0.04 (−0.15 to 0.07) 0.44
4 (1200) 25.8 (16.7) 22.0 (13.5–31.5) 7.0–63.0 −0.3 (8.8) −0.05 (−0.16 to 0.05) 0.32
6 (1400) 22.8 (12.4) 21.0 (13–31) 5.0–51.0 −3.3 (6.1) −0.16 (−0.26 to −0.05) 0.005
8 (1600) 21.3 (12.9) 19.0 (13.5–24.5) 7.0–58.0 −4.9 (5.7) −0.22 (−0.33 to −0.12) <0.001
10 (1800) 21.7 (12.1) 19.5 (12.5–29) 8.0–54.0 −4.4 (4.5) −0.18 (−0.29 to −0.07) 0.001
Non‑asthma
0 (0800) 22.3 (14.1) 19.5 (15.5–24.5) 6.0–68.0 – –
2 (1000) 23.6 (14.9) 19.5 (16.5–27.5) 6.0–73.0 1.4 (2.2) 0.06 (−0.05 to 0.18) 0.30
4 (1200) 21.3 (13.9) 17.0 (13.5–27.0) 7.0–66.0 −1.1 (3.0) −0.05 (−0.17 to 0.06) 0.38
6 (1400) 22.8 (18.6) 16.0 (15.0–26.0) 7.0–88.0 0.4 (6.6) −0.02 (−0.14 to 0.09) 0.72
8 (1600) 20.9 (15.4) 17.0 (13.0–23.5) 6.0–72.0 −1.4 (5.9) −0.10 (−0.22 to 0.01) 0.09
10 (1800) 18.5 (11.2) 16.0 (13.0–21.5) 6.0–56.0 −3.8 (5.5) −0.17 (−0.28 to −0.05) 0.005
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CV 0.9–1.5%, intermediate precision CV 1.2–1.7% and 
reproducibility CV 1.7–3.1%), a degree of error of mis-
classification cannot be excluded It should also be noted 
that the assay used has a reproducibility CV of 1.7–3.1% 
around the 50 ng/mL cut point of 1.7–3.1%, introducing 
a degree of reproducibility error when taking repeat sam-
ples [27].
There are a number of methodological limitations 
relevant to the interpretation of the study findings. 
No adjustment has been made for multiple statistical 
testing, thus the findings should be considered illustra-
tive. The findings are generalizable to Caucasian adults 
with asthma on regular ICS and LABA treatment, rep-
resenting GINA Step 3 and 4 therapy [28], but general-
izability to other ethnicities is less certain. ICS reduces 
serum periostin levels [13], FeNO [29–31], and blood 
eosinophil counts [16], however the effect of ICS on 
the circadian rhythm of periostin is not known. Peri-
ostin levels are unlikely to have been influenced by the 
presence or absence of atopy in either the asthma or 
Fig. 3 Individual joined line plots for the fraction of exhaled nitric oxide (FeNO). Panel a shows the asthma group and Panel b shows the non‑
asthma group. The bold red line indicates the median FeNO value
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non-asthma group [12, 13], but It is possible that serum 
periostin levels may show a greater magnitude of cir-
cadian variability in a population in which there is a 
greater proportion with uncontrolled disease, similar 
to an effect shown with FeNO [21]. In this sample there 
were no participants on chronic oral corticosteroids 
however this is a group that might be more likely to be 
considered for monoclonal antibody therapy regardless 
of serum periostin levels. The use of LABA therapy prior 
to the baseline morning measurements and no subse-
quent medication use during the period of the study, is 
unlikely to have influenced the periostin or FeNO levels, 
but may have resulted in the gradual reduction in FEV1 
during the study period as the bronchodilator effect of 
the LABA wore off.
Conclusions
We conclude that there is day-time variation of serum 
periostin in adults with asthma receiving maintenance 
ICS and LABA therapy, with higher levels in the morning. 
The magnitude of the variation in serum periostin levels 
is of uncertain clinical significance, however, the time of 
day at which the blood sample is drawn was unlikely to 
influence treatment decisions if a specific serum peri-
ostin level was used to predict treatment responsiveness 
in the asthma group.
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